At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Buparlisibdrug
Likely dose
Buparlisib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Phase II Study of BKM120 in Subjects With Relapsed and Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma
In Brief
A Phase 2 clinical trial evaluating Buparlisib for Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. Completed, enrolled 72 participants across 20 sites in 8 countries.
Detailed Summary
This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, France, Germany, Italy, South Korea, Spain, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartFeb 2013
Primary CompletionJul 2017
TodayJul 2026
First PostedSep 26, 2012
Enrollment StartFeb 28, 2013
Primary CompletionJul 21, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.8 years ago
Interventions
Buparlisibdrug
100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days